NEDD9 and Familial prostate cancer: This is complementary with our predictions, suggesting that after being regulated by KLF6, ZFP36 directly binds to NEDD9 (Fig 2), thus acting as another novel upstream inhibitor of NFκB with a role in the amelioration of prostate cancer.